BioGaia AB: Year-end report January – December 2022
FOURTH QUARTER 2022 · Net sales amounted to SEK 274.3 million (206.2), an increase of SEK 68.1 million, or 33% (excluding foreign exchange effects, 19%) of which the acquisition of Nutraceutics accounted for an increase of SEK 29.9 million (15%). Organic growth was 5%. · Net sales in the Paediatrics segment amounted to SEK 207.4 million (150.1), an increase of 38% (excluding foreign exchange effects, 24%). · Net sales in the Adult Health segment amounted to SEK 64.7 million (55.2), an increase of 17% (excluding foreign exchange effects, 5%). · Operating expenses amounted to